Understanding how fat tissue affects diabetes remission after weight loss surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the relationship between adipose tissue metabolic changes and the remission of Type 2 Diabetes (T2D) following bariatric surgery. Participants will undergo bariatric surgery and be divided into two groups based on their T2D status. The study involves multiple metabolic sessions before and after surgery, where participants will receive stable tracers, consume a liquid meal, and undergo PET and MRI imaging. The trial aims to determine the role of niacin in regulating lipid metabolism and its impact on glucose production in T2D patients post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 65
* BMI 35 kg/m2
* Diagnosed T2D - according to Diabetes Canada diagnostics criteria.
* Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria.
* Women with a negative serum pregnancy test.

Exclusion Criteria:

* Treatment with an oral contraceptive;
* Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects;
* Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions;
* Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension;
* Smoking or consumption of more than 2 alcoholic beverages per day;
* Any contraindication to MRI;
* A Diabetes Remission (DiaRem) score \>8 (low probability of T2D remission);
* Having participated to a research study with exposure to radiation in the last two years before the start of the study;
* Pregnant or breastfeeding women;
* Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET/CT scanners.
* Being allergic to eggs

Where it's running

• centre de recherche du CHUS
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: André Carpentier, MD — Université de Sherbrooke
• Study coordinator: Frédérique Frisch
• Email: frederique.frisch@usherbrooke.ca
• Phone: 1-819-346-1110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proliverenol for liver fat and insulin resistance in type 2 diabetes

  This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.

  Recruiting Phase 2 Universitas Sriwijaya · Palembang, South Sumatera · NCT07928661

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.